Advertisement
Advertisement
August 12, 2026
Bracco VueJect Ultrasound Contrast Delivery System Receives FDA Clearance, Health Canada Authorization
KEY TAKEAWAYS
- Bracco Imaging received FDA 510(k) clearance and Health Canada authorization for its VueJect ultrasound contrast delivery system.
- The system is designed to provide continuous ultrasound contrast administration during cardiac imaging procedures.
- VueJect will initially be available in the United States and Canada, with additional regulatory submissions planned in other markets.
August 12, 2026—Bracco Imaging announced United States FDA 510(k) clearance and Health Canada authorization for VueJect, the company’s ultrasound contrast delivery system designed to support cardiology imaging.
According to the company, VueJect will initially be available in the United States and Canada. Additional regulatory submissions are planned in other markets as part of the company’s broader global commercialization strategy for VueJect, noted Bracco.
As part of Bracco’s integrated contrast-enhanced ultrasound ecosystem, VueJect is intended to improve workflow efficiency with a streamlined contrast administration process, reduce operator variability for consistency during contrast administration, and enable continuous administration of ultrasound contrast agents to support more consistent enhancement during cardiac imaging procedures, stated the company.
Advertisement
Advertisement
